PMID- 38322591
OWN - NLM
STAT- MEDLINE
DCOM- 20240208
LR  - 20240312
IS  - 1449-1907 (Electronic)
IS  - 1449-1907 (Linking)
VI  - 21
IP  - 3
DP  - 2024
TI  - Association of sodium-glucose cotransporter 2 inhibitors with the incidence of 
      corneal diseases in type 2 diabetes mellitus.
PG  - 583-592
LID - 10.7150/ijms.91571 [doi]
AB  - Sodium-glucose cotransporter 2 (SGLT2) inhibitors revealed the protective 
      function on various systemic diseases. This study aimed to determine whether the 
      usage of SGLT2 inhibitors associates with incidences of superficial keratopathy 
      and infectious keratitis in type 2 diabetes mellitus (T2DM) patients. A 
      retrospective cohort study with the usage of National Health Insurance Research 
      Database of Taiwan was conducted. The T2DM patients were divided into the SGLT2 
      inhibitors and control groups according to the usage of SGLT2 inhibitors or not. 
      The major outcomes were defined as the occurrence of superficial keratopathy and 
      infectious keratitis. There were 766 and 1037 episodes of superficial keratopathy 
      in the SGLT2 inhibitors and control groups and SGLT2 inhibitors group showed a 
      significantly lower incidence of superficial keratopathy than the control group 
      (aHR: 0.721, 95% CI: 0.656-0.791, P < 0.0001). Also, there were 166 and 251 
      infectious keratitis events in the SGLT2 inhibitors and control groups and 
      patients in the SGLT2 inhibitors group revealed a significantly lower infectious 
      keratitis incidence than those in the control group (aHR: 0.654, 95% CI: 
      0.537-0.796, P < 0.0001). In addition, the patients that received SGLT2 
      inhibitors demonstrated lower cumulative incidences of both superficial 
      keratopathy and infectious keratitis compared to the non-SGLT2 inhibitors users 
      (both P < 0.0001). In conclusion, the usage of SGLT2 inhibitors correlates to 
      lower incidence of superficial keratopathy and infectious keratitis in T2DM 
      individuals, which is more significant in patients with persistent SGLT2 
      inhibitors application.
CI  - (c) The author(s).
FAU - Tsai, Tsan-Yu
AU  - Tsai TY
AD  - Department of Ophthalmology, Show Chwan Memorial Hospital, Changhua, Taiwan.
FAU - Yang, Po-Jen
AU  - Yang PJ
AD  - Department of Family and Community Medicine, Chung Shan Medical University 
      Hospital, Taichung, Taiwan.
AD  - School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
FAU - Chao, Shih-Chun
AU  - Chao SC
AD  - Department of Ophthalmology, Show Chwan Memorial Hospital, Changhua, Taiwan.
AD  - Department of Optometry, Central Taiwan University of Science and Technology, 
      Taichung, Taiwan.
AD  - Department of Optometry, Yuan Pei University, Hsinchu, Taiwan.
FAU - Lee, Chia-Yi
AU  - Lee CY
AD  - Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
AD  - Department of Ophthalmology, Nobel Eye Institute, Taipei, Taiwan.
AD  - Department of Ophthalmology, Jen-Ai Hospital Dali Branch, Taichung, Taiwan.
FAU - Huang, Jing-Yang
AU  - Huang JY
AD  - Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
AD  - Department of Medical Research, Chung Shan Medical University Hospital, Taichung, 
      Taiwan.
FAU - Yang, Shun-Fa
AU  - Yang SF
AD  - Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
AD  - Department of Medical Research, Chung Shan Medical University Hospital, Taichung, 
      Taiwan.
FAU - Lin, Hung-Yu
AU  - Lin HY
AD  - Department of Ophthalmology, Show Chwan Memorial Hospital, Changhua, Taiwan.
AD  - Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
AD  - Department of Post-Baccalaureate Medicine, College of Medicine, National Chung 
      Hsing University, Taichung, Taiwan.
AD  - Department of Optometry, Chung Shan Medical University, Taichung, Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20240120
PL  - Australia
TA  - Int J Med Sci
JT  - International journal of medical sciences
JID - 101213954
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Humans
MH  - *Corneal Diseases/complications
MH  - *Diabetes Mellitus, Type 2/complications
MH  - Hypoglycemic Agents
MH  - Incidence
MH  - *Keratitis/complications
MH  - Retrospective Studies
MH  - *Sodium-Glucose Transporter 2 Inhibitors
PMC - PMC10845264
OTO - NOTNLM
OT  - SGLT2 inhibitors
OT  - age
OT  - epidemiology
OT  - infectious keratitis
OT  - superficial keratopathy
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2024/02/07 06:42
MHDA- 2024/02/08 06:43
PMCR- 2024/01/01
CRDT- 2024/02/07 04:03
PHST- 2023/10/26 00:00 [received]
PHST- 2024/01/10 00:00 [accepted]
PHST- 2024/02/08 06:43 [medline]
PHST- 2024/02/07 06:42 [pubmed]
PHST- 2024/02/07 04:03 [entrez]
PHST- 2024/01/01 00:00 [pmc-release]
AID - ijmsv21p0583 [pii]
AID - 10.7150/ijms.91571 [doi]
PST - epublish
SO  - Int J Med Sci. 2024 Jan 20;21(3):583-592. doi: 10.7150/ijms.91571. eCollection 
      2024.